VivoSeq
Other

Lynch Syndrome

7

Pipeline Programs↗

7

Active Trials↗

5

Companies Involved↗

Lynch syndrome is an early-stage landscape with 7 programs across 5 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Bristol-Myers Squibb, Alnylam Pharmaceuticals. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

15/100

Mech. Concentration

50/100

Completion Rate

50/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2S

Sichuan Baili Pharmaceutical Co., Ltd.

1 program

Phase 3Bayer logo

Bayer

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

60%

Small molecule

6 of 10 classified programs — the dominant modality here.

40%ALL OTHERSVaccine330%Monoclonal antibody110%

Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 12 pipeline programs.

Analysis

Trial Status

10

clinical trials

Not yet recruiting3 · 30%
Active, not recruiting2 · 20%
Recruiting2 · 20%
Completed1 · 10%
Unknown status1 · 10%
Terminated1 · 10%

Clinical Trials

Trial Activity

10 trials

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05411718·40 enrolled
First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptides for the Prevention of Cancer in of Lynch Syndrome Carriers
Recruiting·FFundacion Clinic per a la Recerca Biomédica·Phase 1·NCT07163403·20 enrolled
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT05419011·186 enrolled
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
Active, not recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT05078866·45 enrolled
Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers
Not yet recruiting·TTel-Aviv Sourasky Medical Center·Phase 3·NCT02497820·1,800 enrolled
Preventive Dendritic Cell Vaccination for Lynch Syndrome
Not yet recruiting·RRadboud University Medical Center·Phase 1/2·NCT07412197·23 enrolled
Let's Talk: Overcoming Barriers to Uptake of Cascade Screening Through a Stakeholder-informed Online Intervention
Not yet recruiting·UUNC Lineberger Comprehensive Cancer Center·Preclinical·NCT07304063·20 enrolled
Atorvastatin ± Aspirin in Lynch Syndrome Syndrome
Completed·FFox Chase Cancer Center·Phase 1·NCT04379999·43 enrolled
Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy
Terminated·—·Phase 2·NCT03631641·3 enrolled
PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients
Unknown status·SSun Yat-sen University·Phase 3·NCT04711434·260 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)